A Phase 3, Multicenter, Randomized, Open-label Study of Orally Administered AG-221 Versus Conventional Care Regimens in Subjects with Isocitrate Dehydrogenase 2 Mutation Positive Acute Myeloid Leukemia Refractory to or Relapsed after First-line Therapy